Auto-generated from public data. Not the firm's stated position.
Sciety appears to focus on early-stage biotech and healthtech companies in the pre-seed through Series B range, with recent portfolio activity suggesting an emphasis on specialized medical devices and therapeutic platforms. Based on disclosed check sizes of €0.1M to €1.5M and portfolio companies spanning blood sampling, peptide synthesis, and wound care, the firm seems to target innovative solutions addressing specific clinical or laboratory needs.
Generated 2 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.